We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MRK, Daiichi Begin Pivotal Esophageal Cancer Study With ADC Drug
Read MoreHide Full Article
Merck (MRK - Free Report) and Japan’s Daiichi Sankyo announced the dosing of the first patient in the phase III IDeate-Esophageal01 study evaluating their B7-H3 directed DXd antibody-drug conjugate (ADC), ifinatamab deruxtecan (I-DXd), in certain patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC).
The IDeate-Esophageal01 study will evaluate the safety and efficacy of I-DXd versus an investigator’s choice of chemotherapy in ESCC patients whose disease progressed following treatment with a platinum-containing systemic therapy and an immune checkpoint inhibitor.
The initiation of the IDeate-Esophageal01 study is based on data from the phase I/II IDeate-PanTumor01 study in which I-DXd demonstrated promising responses in heavily pretreated patients with ESCC.
The primary endpoint of the IDeate-Esophageal01 study will be overall survival, while secondary endpoints include progression-free survival and objective response rate as assessed by blinded independent central review and safety.
MRK Stock Performance
Year to date, shares of Merck have plunged 22.3% compared with the industry’s decline of 5.2%.
Image Source: Zacks Investment Research
MRK & Daiichi's Deal for I-DXd & Other ADC Candidates
Besides esophageal cancer, I-DXd is being evaluated in a phase III study for treating small cell lung cancer (SCLC). The ADC drug candidate is also being evaluated both as monotherapy and in combination with other therapies in several early-to-mid-stage studies for treating extensive-stage small cell lung cancer (ES-SCLC) and other solid tumors.
Merck acquired global co-development and co-commercialization rights to I-DXd and two other ADCs, patritumab deruxtecan and raludotatug deruxtecan, from Daiichi Sankyo in October 2023 for a total potential consideration of up to $22 billion. However, Daiichi Sankyo has retained exclusive rights for the development of the candidates in Japan.
In August last year, Merck expanded the collaboration to co-develop and co-commercialize MK-6070, an investigational T-cell engager targeting delta-like ligand 3 (DLL3), which it obtained from its recent acquisition of Harpoon Therapeutics.
Last June, the FDA issued a complete response letter (“CRL”) to the biologics license application seeking accelerated approval for patritumab deruxtecan for previously-treated EGFR-mutated non-small cell lung cancer. The CRL was based on observations made after the inspection of a third-party manufacturing facility.
Raludotatug deruxtecan is being developed in mid-stage studies for ovarian cancer as well as other cancer indications.
Stiff Competition in the ADC Space
ADCs are being considered a disruptive innovation in the pharmaceutical industry as these will enable better treatment of cancer by harnessing the targeting power of antibodies to deliver cytotoxic molecule drugs to tumors.
Daiichi Sankyo has several ADCs in clinical development across multiple types of cancer. It markets Enhertu, a HER2-directed ADC, in partnership with AstraZeneca (AZN - Free Report) , which is presently approved across multiple indications, including HER2-mutated breast, lung and gastric cancers.
In January 2025, the FDA approved AZN and Daiichi’s second ADC drug, Datroway, for treating unresectable or metastatic HR-positive, HER2-negative breast cancer in adult patients who have received prior endocrine-based therapy and chemotherapy.
Pfizer (PFE - Free Report) also entered into the ADC space with the acquisition of Seagen in late 2023 for $43 billion.
Post this acquisition, PFE added three ADCs to its portfolio — Adcetris, Padcev and Tivdak — all approved across solid tumors and hematologic malignancies. These products contributed meaningfully to Pfizer’s revenues in 2024.
Image: Shutterstock
MRK, Daiichi Begin Pivotal Esophageal Cancer Study With ADC Drug
Merck (MRK - Free Report) and Japan’s Daiichi Sankyo announced the dosing of the first patient in the phase III IDeate-Esophageal01 study evaluating their B7-H3 directed DXd antibody-drug conjugate (ADC), ifinatamab deruxtecan (I-DXd), in certain patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC).
The IDeate-Esophageal01 study will evaluate the safety and efficacy of I-DXd versus an investigator’s choice of chemotherapy in ESCC patients whose disease progressed following treatment with a platinum-containing systemic therapy and an immune checkpoint inhibitor.
The initiation of the IDeate-Esophageal01 study is based on data from the phase I/II IDeate-PanTumor01 study in which I-DXd demonstrated promising responses in heavily pretreated patients with ESCC.
The primary endpoint of the IDeate-Esophageal01 study will be overall survival, while secondary endpoints include progression-free survival and objective response rate as assessed by blinded independent central review and safety.
MRK Stock Performance
Year to date, shares of Merck have plunged 22.3% compared with the industry’s decline of 5.2%.
Image Source: Zacks Investment Research
MRK & Daiichi's Deal for I-DXd & Other ADC Candidates
Besides esophageal cancer, I-DXd is being evaluated in a phase III study for treating small cell lung cancer (SCLC). The ADC drug candidate is also being evaluated both as monotherapy and in combination with other therapies in several early-to-mid-stage studies for treating extensive-stage small cell lung cancer (ES-SCLC) and other solid tumors.
Merck acquired global co-development and co-commercialization rights to I-DXd and two other ADCs, patritumab deruxtecan and raludotatug deruxtecan, from Daiichi Sankyo in October 2023 for a total potential consideration of up to $22 billion. However, Daiichi Sankyo has retained exclusive rights for the development of the candidates in Japan.
In August last year, Merck expanded the collaboration to co-develop and co-commercialize MK-6070, an investigational T-cell engager targeting delta-like ligand 3 (DLL3), which it obtained from its recent acquisition of Harpoon Therapeutics.
Last June, the FDA issued a complete response letter (“CRL”) to the biologics license application seeking accelerated approval for patritumab deruxtecan for previously-treated EGFR-mutated non-small cell lung cancer. The CRL was based on observations made after the inspection of a third-party manufacturing facility.
Raludotatug deruxtecan is being developed in mid-stage studies for ovarian cancer as well as other cancer indications.
Stiff Competition in the ADC Space
ADCs are being considered a disruptive innovation in the pharmaceutical industry as these will enable better treatment of cancer by harnessing the targeting power of antibodies to deliver cytotoxic molecule drugs to tumors.
Daiichi Sankyo has several ADCs in clinical development across multiple types of cancer. It markets Enhertu, a HER2-directed ADC, in partnership with AstraZeneca (AZN - Free Report) , which is presently approved across multiple indications, including HER2-mutated breast, lung and gastric cancers.
In January 2025, the FDA approved AZN and Daiichi’s second ADC drug, Datroway, for treating unresectable or metastatic HR-positive, HER2-negative breast cancer in adult patients who have received prior endocrine-based therapy and chemotherapy.
Pfizer (PFE - Free Report) also entered into the ADC space with the acquisition of Seagen in late 2023 for $43 billion.
Post this acquisition, PFE added three ADCs to its portfolio — Adcetris, Padcev and Tivdak — all approved across solid tumors and hematologic malignancies. These products contributed meaningfully to Pfizer’s revenues in 2024.
MRK's Zacks Rank
Merck currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.